Obesity Market Could See Two Near-Term Entrants; Pfizer Says Combo Is Key
This article was originally published in Pharmaceutical Approvals Monthly
Obesity market could see two near-term entrants, Pfizer says. Sanofi-Aventis will submit Acomplia in early Q2 2005; Regeneron’s Axokine is in Phase III. Pfizer is looking at combination therapy for metabolic syndrome, including Caduet and atorvastatin/torcetrapib. Firms are focusing on cardiovascular benefits
You may also be interested in...
Kos is targeting an NDA for its Niaspan/simvastatin combination product for 2006, following the completion of two pivotal trials in patients with mixed dyslipidemia.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011